| Sphingolipids control dermal fibroblast heterogeneity L Capolupo, I Khven, AR Lederer, L Mazzeo, G Glousker, S Ho, F Russo, ... Science 376 (6590), eabh1623, 2022 | 80 | 2022 |
| Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation A Clocchiatti, S Ghosh, MG Procopio, L Mazzeo, P Bordignon, P Ostano, ... The Journal of clinical investigation 128 (12), 5531-5548, 2018 | 52 | 2018 |
| An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors M Mancini, H Gal, N Gaborit, L Mazzeo, D Romaniello, TM Salame, ... EMBO Molecular Medicine 10 (2), 294-308, 2018 | 47 | 2018 |
| A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways D Romaniello, L Mazzeo, M Mancini, I Marrocco, A Noronha, M Kreitman, ... Clinical Cancer Research 24 (22), 5610-5621, 2018 | 44 | 2018 |
| Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis M Ma, S Ghosh, D Tavernari, A Katarkar, A Clocchiatti, L Mazzeo, ... Journal of Experimental Medicine 218 (2), e20201137, 2020 | 35 | 2020 |
| Sphingolipid control of fibroblast heterogeneity revealed by single-cell lipidomics L Capolupo, I Khven, L Mazzeo, G Glousker, F Russo, JP Montoya, S Ho, ... Biorxiv, 2021.02. 23.432420, 2021 | 14 | 2021 |
| ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation L Mazzeo, S Ghosh, E Di Cicco, J Isma, D Tavernari, A Samarkina, ... Nature Communications 15 (1), 1038, 2024 | 2 | 2024 |
| Nuclear lamin A/C phosphorylation by loss of Androgen Receptor is a global determinant of cancer-associated fibroblast activation S Ghosh, J Isma, L Mazzeo, A Toniolo, C Simon, GP Dotto bioRxiv, 2023 | 1 | 2023 |
